<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940523-0-00036</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4700 -->  <!-- PJG ITAG l=11 g=1 f=1 --> The desired gene(s) may be introduced into a host plant by one of several methods, including: (1) Direct DNA uptake by the plant cells mediated by chemical or electrical treatments; (2) microinjection of DNA directly into plant cells; (3) biolistics, or firing tiny particles coated with the DNA of interest into plant cells; and (4) the use of a bacterium, such as the soil bacterium  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Agrobacterium tumefaciens,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> as a vehicle to carry the DNA into plant cells. (For a discussion of these processes, see Ref. 4). <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=1 --> B. Need for a Selectable Marker <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Transformation of plant cells by introducing exogenous DNA is an inefficient process and, in general, only a small proportion of cells will successfully take up, integrate, and express the new genetic material (Ref. 5). Further, the few cells that do so are not readily distinguishable from the vast majority of cells that do not. Therefore, developers of transgenic plants need a means to distinguish cells that are successfully transformed from those that are not. Selectable markers, such as the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> kan <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> r <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  gene, perform this function. <!-- PJG 0012 frnewline --> The  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> kan <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> r <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  gene is linked to the gene (or genes) of interest and then this genetic material is inserted into plant cells. Because plant cells are sensitive to the antibiotic kanamycin, incorporation of the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> kan <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> r <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  gene into cells and subsequent expression of APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II provides a convenient method for selecting successfully transformed cells.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Kan <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> r <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  works as a marker because only successfully transformed cells (which contain both the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> kan <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> r <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  and the desired genetic material) survive when grown in a kanamycin-containing medium. These cells are subsequently regenerated into transgenic plants.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=1 --> C. Identity of the Additive <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 1 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  (CAS Reg. No. 58943&hyph;39&hyph;8) is encoded by the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> kan <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> r <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  gene, which was originally isolated as a component of transposon Tn <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 5 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  from the bacterium  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Escherichia coli  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (Refs. 6 and 7). APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II is an enzyme with an apparent molecular weight of 25,000 that catalyzes the transfer of a phosphate group from adenosine 5 <!-- PJG 0020 minuteslatlong --> &rsquo;-triphosphate (ATP) to a hydroxyl group of aminoglycoside antibiotics (see below), thereby inactivating the antibiotics. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <FOOTNOTE> <FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=5 f=1 --> 1 <!-- PJG /ITAG -->  </FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 --> Other names for this enzyme include neomycin phosphotransferase II (NPT II), neomycin phosphotransferase, and kanamycin phosphotransferase II. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FOOTNOTE>  <FOOTNOTE> <FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=5 f=1 --> 2 <!-- PJG /ITAG -->  </FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 --> A transposon is a segment of DNA that is mobile and has the capacity to move from one site in the genome to another. Transposons vary in size and frequently contain, as does Tn <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=3 --> 5 <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=1 --> , antibiotic resistance genes in addition to genes coding for functions concerned with movement of the transposon. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </FOOTNOTE>  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II inactivates the aminoglycoside antibiotics neomycin, kanamycin, paromomycin, ribostamycin, gentamicins A and B, as well as butirosins (Refs. 8 and 9). Of the antibiotics that are inactivated by APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II, only neomycin and kanamycin are currently approved for use in humans or animals in the United States (Refs. 10 and 11). <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 3 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <FOOTNOTE> <FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=5 f=1 --> 3 <!-- PJG /ITAG -->  </FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 --> Gentamicin, which is used therapeutically, is composed of a complex mixture of the antibiotic substances produced by  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=3 --> Micromonospora purpurea  <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=1 --> that contain primarily gentamicin C <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=5 f=2 --> 1 <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=1 -->  (25 to 50 percent), gentamicin C <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=5 f=2 --> 1a <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=1 -->  (10 to 35 percent), and gentamicins C <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=5 f=2 --> 2a <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=1 -->  and C <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=5 f=2 --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=28 g=1 f=1 -->  (25 to 55 percent) (Ref. 10). Gentamicins A and B are at most minor components of the commercial drug. Thus, APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II does not confer resistance to gentamicin that is used therapeutically (Ref. 12). <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </FOOTNOTE>  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II evaluated in this document is the enzyme whose synthesis is directed by the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> kan <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> r <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  gene derived from transposon Tn <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 5 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . This enzyme is not to be confused with enzymes that may be similarly named (e.g., a type I aminoglycoside phosphotransferase encoded by a gene isolated from transposon Tn601) or other bacterial enzymes (including acetyltransferases, nucleotidyltransferases, and phosphotransferases) that inactivate kanamycin and neomycin (Refs. 8 and 12). <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=1 --> D. Use and Intended Technical Effects <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Aminoglycoside antibiotics exert their effect on bacteria by binding to bacterial ribosomes and inhibiting protein synthesis. Phosphorylation of the antibiotics by APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II interferes with this binding and thus prevents the antibiotics from inhibiting protein synthesis (Ref. 13). In this way, cells that contain the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> kan <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> r <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  gene and that express APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II are rendered resistant to the action of the antibiotics. In plant cells, the antibiotics exert their effect on mitochondria and chloroplasts where protein synthesis takes place on ribosomes that resemble bacterial ribosomes (Ref. 14). <!-- PJG 0012 frnewline --> The proposed use of the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> kan <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> r <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  gene and gene product APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II is as a processing aid in the development of new varieties of tomato, cotton, and oilseed rape intended for food use. As discussed above, because transformation of plant cells is an inefficient process, the presence of APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II and the consequent ability of the plant cells to grow in the presence of antibiotics is used to distinguish between transformed and nontransformed cells. Therefore, the intended technical effect of APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II is to permit, in the early phases of development of genetically modified plants, the selection of transformants carrying the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> kan <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> r <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  gene along with the genetic material of interest. However, APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II has no intended technical effect in the final plant or final crop product. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> III. Safety Evaluation <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=1 --> A. APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Safety issues associated with APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II can be divided into two areas: (1) Those associated with the direct effects of ingestion of the protein, including the possibility of allergenicity; and (2) those associated with the biological activity of APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II (i.e., the effect of the enzyme on the therapeutic efficacy of orally administered antibiotics). <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            